In-vitro toxicology testing market size worth $51.1 billion by 2028

The global in-vitro toxicology testing market size is expected to reach USD 51.1 billion by 2028, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 10.7% from 2021 to 2028. In recent times, the validation and acceptance of in-vitro and alternative testing methods by regulatory agencies are increasing at lucrative pace. Also, ongoing technological advancements to replace the use of animals for toxicology testing purposes have spurred the use of in vitro testing models, in turn, driving the market.

Several governments are taking measures to minimize animal-based test models, forming conducive government policies, and providing funds to support in-vitro models. These factors are expected to create ample growth opportunities for the market. For instance, in November 2019, the U.S. National Institute for Environmental Health Sciences planned to provide funds to small companies for the development of engineered 3D culture or organotypic culture models (OCM) in-vitro systems.

With advancements in high throughput screening, biological screening, and chemical synthesis, the number of publicly available databases containing data related to toxicity; absorption, distribution, metabolism, and excretion (ADME); pharmacovigilance; and drug screening has expanded rapidly. This has enabled scientists to access vast information for toxicity profiling, thereby spurring revenue generation in this market. Several companies offer HTT-based in vitro toxicology analysis, e.g., Solidus Bioscience’s MetaChip Technology, which provides a solution for in vitro toxicology analysis using HTT. PR Newswire